Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | SHBG | P04278 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22462729 | 1.00 | NOS3 (0.33) | NOS3NOS1NOS2ROCK2ROCK1 | |
| SCHEMBL5422 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL25285379 | 0.96 | — | — | |
| Ammonia Solution, Strong SCHEMBL16487287 | 0.96 | — | — | |
| SCHEMBL22349300 | 0.89 | MEN1 (0.36) | ROCK2ROCK1 | |
| SCHEMBL21539856 | 0.89 | MEN1 (0.36) | ROCK2ROCK1 | |
| SCHEMBL16191246 | 0.89 | OPRM1 (0.31) | ROCK2ROCK1 | |
| SCHEMBL24210496 | 0.89 | SHBG (0.35) | ROCK2ROCK1SHBG | |
| SCHEMBL7979 | 0.86 | TRPA1 (0.39) | — | |
| SCHEMBL452781 | 0.86 | TRPA1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4605742-A | Process for the production of piperidine | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1986-08-12 | — | — | US | claimed |
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | ALPHA-9 ONCOLOGY INC. (CA) | 2024-01-18 | — | — | US | disclosed |
| US-20230301173-A1 | ELECTRONIC SWITCHING DEVICE | MERCK PATENT GMBH (DE) | 2023-09-21 | — | — | US | disclosed |
| US-11739085-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2023-08-29 | — | — | US | disclosed |
| WO-2023131170-A1 | DOUBLE-STRANDED RNA HAVING NUCLEOTIDE ANALOG | 大睿生物医药科技(上海)有限公司 | 2023-07-13 | — | — | WO | disclosed |
| US-20230210822-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING FATTY LIVER DISEASE | SHIONOGI & CO., LTD. (JP) | 2023-07-06 | — | — | US | disclosed |
| WO-2023071657-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION THEREOF, AND LIQUID CRYSTAL DISPLAY DEVICE | 江苏和成显示科技有限公司 | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20220177449-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-06-09 | — | — | US | disclosed |
| US-20220133734-A1 | SUBSTITUTED 1H-PYRAZOLO[4,3-C]PYRIDINES AND DERIVATIVES AS EGFR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-05 | — | — | US | disclosed |
| US-20200306737-A1 | SYNTHESIS AND APPLICATION OF CHIRAL SUBSTITUTED POLYVINYLPYRROLIDINONES | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION | 2020-10-01 | — | — | US | disclosed |
| US-20190202830-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-20190161501-A1 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT | SHIONOGI & CO., LTD. (JP) | 2019-05-30 | — | — | US | disclosed |
| US-9783735-B2 | Liquid crystal display device and liquid crystal composition used therefor | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-10-10 | — | — | US | disclosed |
| US-8877092-B2 | Liquid-crystalline medium | MERCK PATENT GMBH (DE) | 2014-11-04 | — | — | US | disclosed |
| US-20120326084-A1 | LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-27 | — | — | US | disclosed |
| US-5759528-A | AMINE OXIDE SURFACTANT AND CYCLOHEXANE, CYCLOHEXENE OR CYCLOHEXANONE DERIVATIVE | INSTITUTE FOR ADVANCED SKIN RESEARCH, INC. (JP) | 1998-06-02 | — | — | US | disclosed |
| EP-0745389-A1 | COMPOSITION FOR TOPICAL APPLICATION | INSTITUTE FOR ADVANCED SKIN RESEARCH INC. (JP) | 1996-12-04 | — | — | EP | disclosed |
| US-4605742-A | Process for the production of piperidine | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1986-08-12 | — | — | US | disclosed |
| EP-0019764-A1 | Trans-3-(4'-tert.-butyl-cyclohexyl-1')-2-methyl-1-(3'-methylpiperidino, 3',5'-dimethylpiperidino and 2', 6'-dimethylmorpholino) propane, process for their pure preparation, antimycotic agents containing them and their utilisation | BASF Aktiengesellschaft (DE) | 1980-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120326084-A1 | LIQUID-CRYSTALLINE MEDIUM | NEFM, VIM, PLG | NOS3 4378/4885NOS1 2848/4885NOS2 4304/4885 |
| US-20220177449-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | NOS3 2981/4885NOS1 3506/4885NOS2 4216/4885 |
| US-20220133734-A1 | SUBSTITUTED 1H-PYRAZOLO[4,3-C]PYRIDINES AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB4, ERBB2 | NOS3 1480/4885NOS1 1959/4885NOS2 2906/4885 |
| US-20200306737-A1 | SYNTHESIS AND APPLICATION OF CHIRAL SUBSTITUTED POLYVINYLPYRROLIDINONES | POLRMT, CNBP, DHPS | NOS3 3110/4885NOS1 2719/4885NOS2 2507/4885 |
| US-20230301173-A1 | ELECTRONIC SWITCHING DEVICE | OR10J3, L1CAM, GRM6 | NOS3 1224/4885NOS1 448/4885NOS2 673/4885 |
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | KLK3, FOLH1, TMEM14C | NOS3 4835/4885NOS1 4849/4885NOS2 4809/4885 |
| US-20230210822-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING FATTY LIVER DISEASE | LIPC, PNLIP, ACACB | NOS3 1541/4885NOS1 1792/4885NOS2 908/4885 |
| US-11739085-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | NOS3 4791/4885NOS1 4783/4885NOS2 4813/4885 |
| US-20190202830-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | NOS3 4791/4885NOS1 4783/4885NOS2 4813/4885 |
| US-20190161501-A1 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT | DRD3, DRD4, DRD2 | NOS3 356/4885NOS1 914/4885NOS2 1179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.